Bisphosphonate: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: In medicine, '''bisphosphonates''' are medications which "contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhi...) |
imported>Robert Badgett (Started 'Adverse effects') |
||
| Line 4: | Line 4: | ||
Examples of bisphosphonates include [[alendronate]], [[risedronate]], [[etidronate]], [[ibandronate]], [[pamidronate]], and [[zoledronic acid]]. | Examples of bisphosphonates include [[alendronate]], [[risedronate]], [[etidronate]], [[ibandronate]], [[pamidronate]], and [[zoledronic acid]]. | ||
==Adverse effects== | |||
[[Zoledronic acid]] can increase [[atrial fibrillation]].<ref name="pmid17476007">{{cite journal |author=Black DM, Delmas PD, Eastell R, ''et al.'' |title=Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis |journal=N. Engl. J. Med. |volume=356 |issue=18 |pages=1809–22 |year=2007 |month=May |pmid=17476007 |doi=10.1056/NEJMoa067312 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=17476007&promo=ONFLNS19 |issn=}}</ref> | |||
==References== | ==References== | ||
<references/> | <references/> | ||
Revision as of 12:41, 20 May 2009
In medicine, bisphosphonates are medications which "contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents."[1]
Bisphosphonates are used to prevent fractures among patients with osteoporosis or low bone mass.
Examples of bisphosphonates include alendronate, risedronate, etidronate, ibandronate, pamidronate, and zoledronic acid.
Adverse effects
Zoledronic acid can increase atrial fibrillation.[2]
References
- ↑ Anonymous (2024), Bisphosphonate (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Black DM, Delmas PD, Eastell R, et al. (May 2007). "Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis". N. Engl. J. Med. 356 (18): 1809–22. DOI:10.1056/NEJMoa067312. PMID 17476007. Research Blogging.